About Novo Nordisk A/S
https://www.novonordisk.comNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
CEO
Maziar Mike Doustdar
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-09-20 | Forward | 2:1 |
| 2014-01-09 | Forward | 5:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Goldman Sachs
Buy
Berenberg
Buy
TD Cowen
Buy
Barclays
Equal Weight
BMO Capital
Market Perform
UBS
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
CAPITAL INTERNATIONAL INVESTORS
Shares:17.71M
Value:$1.04B
LOOMIS SAYLES & CO L P
Shares:16.17M
Value:$952.31M
FMR LLC
Shares:14.08M
Value:$829.18M
Summary
Showing Top 3 of 1,795
About Novo Nordisk A/S
https://www.novonordisk.comNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $74.98B ▼ | $33.39B ▲ | $20.01B ▼ | 26.68% ▼ | $4.5 ▼ | $33.76B ▼ |
| Q2-2025 | $76.86B ▼ | $30.56B ▲ | $26.5B ▼ | 34.48% ▼ | $5.96 ▼ | $43.6B ▼ |
| Q1-2025 | $78.09B ▼ | $26.41B ▼ | $29.03B ▲ | 37.18% ▲ | $6.54 ▲ | $46.05B ▲ |
| Q4-2024 | $85.68B ▲ | $35.92B ▲ | $28.23B ▲ | 32.95% ▼ | $6.34 ▲ | $40.3B ▲ |
| Q3-2024 | $71.31B | $26.18B | $27.3B | 38.28% | $6.13 | $37.35B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $32.58B ▲ | $512.29B ▲ | $342.39B ▲ | $169.9B ▲ |
| Q2-2025 | $18.93B ▼ | $482.15B ▼ | $314.09B ▼ | $168.07B ▲ |
| Q1-2025 | $41.55B ▲ | $489.16B ▲ | $350.62B ▲ | $138.54B ▼ |
| Q4-2024 | $26.31B ▼ | $465.8B ▲ | $322.31B ▲ | $143.49B ▲ |
| Q3-2024 | $74.88B | $397.44B | $276.92B | $120.52B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $20.01B ▼ | $46.11B ▲ | $-15.43B ▼ | $-17.1B ▲ | $13.65B ▲ | $32.48B ▲ |
| Q2-2025 | $26.5B ▼ | $40.78B ▲ | $-14.25B ▼ | $-46.23B ▼ | $-20.5B ▼ | $24.51B ▲ |
| Q1-2025 | $29.03B ▲ | $24.59B ▲ | $-6.67B ▲ | $5.45B ▼ | $23.28B ▲ | $10.01B ▲ |
| Q4-2024 | $28.23B ▲ | $12.3B ▼ | $-91.22B ▼ | $36.84B ▲ | $-41.36B ▼ | $-4.26B ▼ |
| Q3-2024 | $27.3B | $43.85B | $-20.9B | $-18.4B | $4.2B | $31.73B |
CEO
Maziar Mike Doustdar
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-09-20 | Forward | 2:1 |
| 2014-01-09 | Forward | 5:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Goldman Sachs
Buy
Berenberg
Buy
TD Cowen
Buy
Barclays
Equal Weight
BMO Capital
Market Perform
UBS
Neutral
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
CAPITAL INTERNATIONAL INVESTORS
Shares:17.71M
Value:$1.04B
LOOMIS SAYLES & CO L P
Shares:16.17M
Value:$952.31M
FMR LLC
Shares:14.08M
Value:$829.18M
Summary
Showing Top 3 of 1,795